Wilcox M H
Clin Microbiol Infect. 2007 Oct;13(10):949-52. doi: 10.1111/j.1469-0691.2007.01792.x. Epub 2007 Aug 13.
Broad-spectrum antibiotics are often associated with a relatively high risk of Clostridium difficile infection (CDI). However, exceptions to this rule, e.g., piperacillin-tazobactam, show that marked inhibition of gut flora is not synonymous with CDI risk. Tigecycline has marked broad-spectrum activity that includes Gram-positive and Gram-negative facultative and obligate anaerobes. Antibiotic susceptibility, gut model and clinical trial data suggest that tigecycline is associated with a relatively low risk of CDI. Further clinical data should be obtained to confirm the results of these initial studies.
广谱抗生素通常与艰难梭菌感染（CDI）的相对高风险相关。然而，这条规则也有例外，例如哌拉西林-他唑巴坦，这表明对肠道菌群的显著抑制并不等同于CDI风险。替加环素具有显著的广谱活性，包括革兰氏阳性菌和革兰氏阴性兼性厌氧菌及专性厌氧菌。抗生素敏感性、肠道模型和临床试验数据表明，替加环素与相对较低的CDI风险相关。应获取更多临床数据以证实这些初步研究的结果。
